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Purpose: The association between autoimmune thyroid diseases (AITDs) and vita-
min D deficiency is controversial. We aimed to evaluate the relationship between se-
rum 25-hydroxy-vitamin D3 [25(OH)D3] and anti-thyroid antibody levels. Materials 
and Methods: 25(OH)D3, anti-thyroid antibodies, and thyroid function measured in 
304 patients who visited the endocrinology clinic were analyzed. The patients were 
subgrouped into the AITDs or non-AITDs category according to the presence or ab-
sence of anti-thyroid antibodies. The relationship between anti-thyroid peroxidase 
antibody (TPOAb) and 25(OH)D3 was evaluated. Results: The patients with elevat-
ed anti-thyroid antibodies had lower levels of serum 25(OH)D3 than those who did 
not (12.6±5.5 ng/mL vs. 14.5±7.3 ng/mL, respectively, p<0.001). Importantly, after 
adjusting for age, sex, and body mass index, a negative correlation (r=-0.252, 
p<0.001) was recognized between 25(OH)D3 and TPOAb levels in the AITDs 
group, but this correlation did not exist in the non-AITDs group (r=0.117, p=0.127). 
25(OH)D3 level was confirmed as an independent factor after adjusting for co-fac-
tors that may affect the presence of TPOAb in the AITDs group. Conclusion: 
25(OH)D3 level is an independent factor affecting the presence of TPOAb in AITDs. 
The causal effect of 25(OH)D3 deficiency to AITDs is to be elucidated.
Key Words:   Vitamin D deficiency, anti-thyroid peroxidase antibody, autoimmune 
thyroiditis
INTRODUCTION
The discovery of vitamin D receptor in most tissues and cells in the human body 
has provided new insights into the function of vitamin D as a unique hormone.1 
Many studies have shown that vitamin D can play a role in decreasing the risk of 
chronic illnesses, including autoimmune, infectious, and cardiovascular diseases.2-7 
Furthermore, the role of vitamin D as an immune-modulator has been reported in 
recent years, and low levels of vitamin D have been observed in several autoim-
mune diseases, including autoimmune thyroid diseases (AITDs).8-10 It has been es-
timated that more than 1 billion people worldwide have vitamin D deficiency {se-
rum 25-hydroxy-vitamin D3 [25(OH)D3] below 20 ng/mL} or insufficiency 
[25(OH)D3 of 21-29 ng/mL]. Elderly people as well as children and young adults 
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bott Ireland Diagnostic Division, Lisnamuck, Longford, 
Co. Longford, Ireland). Serum levels of TSHRAb (normal 
range: 0-1.75 IU/L), and TPOAb (threshold value: 0-13.7 
IU/mL) were measured by an electro-chemiluminescence 
immunoassay according to standard protocols (COBAS, 
Roche Diagnostics GmbH, Mannheim, Germany). 
Vitamin D measurements
Serum 25(OH)D3 levels were measured by a radioimmunoas-
say kit (DiaSorin, Inc., Stillwater, MN, USA; normal range: 
9.3-37.6 ng/mL). Quantitative determination of 25(OH)D3 
was carried out by a direct, competitive chemiluminescence 
immunoassay. Specifically, magnetic particles (solid phase) 
were coated with a specific antibody to vitamin D, and vita-
min D was linked to an isoluminol derivative. During the 
incubation, 25(OH)D3 was dissociated from its binding pro-
tein and competed with labeled vitamin D for binding sites 
on the antibody. After the incubation, the unbound material 
was removed with a wash cycle, the starter reagents were 
added, and a flash chemiluminescent reaction was initiated. 
The light signal was measured by an photomultiplier as rel-
ative light units and was inversely proportional to the con-
centration of 25(OH)D3 present in calibrators, controls, or 
samples. 
Ultrasonographic evaluation
Ultrasonographic evaluation of the thyroid gland was per-
formed with an HDI 3000 or HDI 5000 system (Philips 
Medical Systems, Bothell, WA, USA) or an Acuson Sequoia 
512 system (Siemens Medical Solutions, Mountain View, 
CA, USA). Three well-trained radiologists performed a re-
al-time sonographic exam and interpreted the results. Ultra-
sonographic features of diffuse thyroiditis were defined us-
ing the generally accepted standards of diffuse parenchymal 
hypoechogenicity or a heterogeneous echogenic pattern of 
thyroid gland.
Statistical analysis 
Comparison of categorical variables between groups was 
performed using chi-square test and Fisher’s exact test (two-
tailed), as appropriate. Continuous variables are expressed as 
mean±standard deviation. The Student’s t-test and Mann-
Whitney U test was used for comparison of mean values be-
tween groups. Statistical comparisons between groups were 
performed using the chi-square test. Spearman correlations 
were used to examine relationships between the log-trans-
formed TPOAb titer and age, body mass index (BMI), 
are potentially at high risk for vitamin D deficiency.1,11-14 
Furthermore, in South Korea, it is now a greater threat to the 
younger generation, especially to those in the age of 20-29 
and in young adults.15 Females have an especially higher 
prevalence of AITDs.16,17 Hence, we hypothesized that there 
may be an association between vitamin D levels and AITDs.
A few studies have examined the relationship between 
vitamin D insufficiency or deficiency and prevalence of 
AITDs in humans. However, whether a definite association 
between these two conditions exists is still controversial. 
One recent study showed that the prevalence of vitamin D 
deficiency is higher in patients with AITDs and that the 
presence of anti-thyroid antibodies is significantly more 
common in patients with vitamin D deficiency than in those 
with higher vitamin D levels.8 In contrast, another study 
performed in India revealed a weak association between 
low vitamin D levels and AITDs. To elucidate the correla-
tion between vitamin D and AITDs, we analyzed vitamin D 
levels in thyroid disease patients and evaluated the relation-
ship between anti-thyroid peroxidase antibody (TPOAb) 




The medical records of Korean patients who visited the en-
docrinology out-patient clinic of Severance Hospital from 
March 2010 to June 2011 were reviewed. All patients under-
went a thyroid function test and ultrasonography initially for 
the purpose of thyroid evaluation. Serum anti-thyroid anti-
bodies including TPOAb and thyroid stimulating hormone 
(TSH) receptor antibody (TSHRAb) representing Hashimo-
to’s thyroiditis and Graves’ disease respectively, and 25(OH)
D3 were additionally measured in these patients at the first 
visit. The patients taking anti-thyroid drugs or under thyroid 
hormone replacement therapy were excluded. Among these 
patients, 304 were enrolled and subgrouped into either the 
AITDs or the non-AITDs category according to the presence 
or absence of anti-thyroid antibodies, regardless of thyroid 
functional status. This retrospective study was approved by 
our Institutional Review Board, and informed consent was 
not required.
Thyroid function test and anti-thyroid antibodies
Serum TSH, free T4, and T3 were measured by chemilumi-
nescent microparticle immunoassay (Architect System, Ab-
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tients with AITDs was significantly lower than in patients 
with non-AITDs (56.8% vs. 16.1%, 11.9% vs. 16.2%, 
12.6±5.5 ng/mL vs. 14.5±7.3 ng/mL, respectively, p<0.001). 
TPOAb and TSHRAb were also significantly higher in the 
AITDs group than in the non-AITDs group (298.5±336.7 
IU/mL vs. 6.4±2.6 IU/mL, p<0.001 and 5.11±7.97 IU/L vs. 
1.40±3.45 IU/L, p<0.001, respectively). 
Correlation between serum TPOAb and 25(OH)D3 
levels
Table 2 shows the correlation between anti-thyroid antibodies 
and 25(OH)D3. In the AITDs group, the TPOAb level was in-
versely correlated with 25(OH)D3 (r=-0.252, p<0.001) but not 
in the non-AITDs group (r=0.117, p=0.127). TSHRAb was 
not correlateed with 25(OH)D3 levels in either group.
25(OH)D3 is an independent factor of the presence of 
TPOAb
In the multiple regression analysis, only 25(OH)D3 level was 
a major determinant of the presence of TPOAb (odds ratio: 
0.917, 95% confidence interval: 0.858-0.953, p=0.039) after 
adjusting for age, gender, BMI, presence of nodule, goiter, 
and diffuse thyroiditis, which were detected on thyroid ul-
25(OH)D3 and other biochemical variables. Correlations 
were reported as age- and BMI-adjusted. To examine the 
differences in 25(OH)D3 and other biochemical parameters 
between patients with or without TPOAb, a regression mod-
el fit the presence of TPOAb as the dependent variable and 
25(OH)D3 as the independent variable. p-values <0.05 were 
considered statistically significant for all tests. All analyses 
were performed using IBM SPSS software ver. 18.0 (SPSS 




25(OH)D3 levels in AITDs compared to non-AITDs
Baseline characteristics of AITDs and non-AITDs patients 
were compared in Table 1. Among 304 patients, 111 pa-
tients were diagnosed as AITDs (65 patients with Hashimo-
to’s thyroiditis, 46 patients with Graves’ disease). The mean 
of age, gender, serum calcium and phosphorus level, and 
thyroid function test results [except serum triiodothyronine 
(T3) level] were not significantly different between the two 
groups. However, the prevalence of hyperthyroidism and 
hypothyroidism, and mean serum 25(OH)D3 level in the pa-
Table 1. Baseline Characteristics of the Patients According to the Presence of Autoimmune Thyroid Diseases
AITDs (n=111) Non-AITDs (n=193) p value
Age   48.7±12.7   51.1±13.3  0.125
Gender (% male) 19 8  0.088
Ca (mg/dL)   8.92±1.36   8.99±2.20  0.095
P (mg/dL)   3.72±0.84   3.87±0.90  0.126
T3 (ng/mL)   1.55±1.02   1.20±0.62  <0.001
fT4 (ng/dL)   1.41±0.75   1.24±0.67  0.052
TSH (uIU/mL) 1.39 [0.39-3.37] 0.96 [0.82-2.61]  0.572
25(OH)D3 (ng/mL) 12.6±5.5 14.5±7.3   <0.001
Hypothyroidism (%) 16.2 11.9 <0.05
Hyperthyroidism (%) 56.8 16.1 <0.001
TPOAb (IU/mL)   298.5±336.7   6.4±2.6 <0.001
TSHRAb (IU/L)   5.11±7.97   1.40±3.45 <0.001
AITDs, autoimmune thyroid diseases; fT4, free T4; TSH, thyroid stimulating hormone; 25(OH)D3, serum 25-hydroxy-vitamin D3; TPOAb, anti-thyroid peroxi-
dase antibody; TSHRAb, TSH receptor antibody; IQR, interquartile range.
Data presented as median (IQR) for TSH with non-normal distribution. 
Table 2. Correlation between Anti-Thyroid Antibodies and 25(OH)D3 Levels (Adjusted for Age, Sex, and BMI)
25(OH)D3 (AITDs) 25(OH)D3 (non-AITDs)
r p value r p value
TPOAb -0.252 <0.01 0.117 0.127
TSHRAb   0.040      0.660 0.087 0.259
TPOAb, anti-thyroid peroxidase antibody; 25(OH)D3, serum 25-hydroxy-vitamin D3; BMI, body mass index; AITDs, autoimmune thyroid diseases; TSHRAb, 
thyroid stimulating hormone receptor antibody.
TPOAb and 25(OH)D3 were log-transformed.
Low 25(OH)D3 Is Associated with TPOAb in AITDs
Yonsei Med J   http://www.eymj.org   Volume 55   Number 2   March 2014 479
vitamin D level and autoimmune thyroiditis. It is notable 
that a significant association between TPOAb and 25(OH)
D3 level was only found in the AITDs group. This may be 
due to an overall low vitamin D level in the Korean popula-
tion. In fact, the correlation between 25(OH)D3 level and 
TPOAb is also seen in vitamin D level within the range of 
vitamin D deficiency as defined by a recent guideline on 
bone metabolism, suggesting a need of a different reference 
value of vitamin D for this extra-skeletal effect.
This study did not show a seasonal change in vitamin D 
levels. Vitamin D levels were the lowest in the winter, as 
was expected, though the association was not statistically 
significant. This may have been because the majority of the 
patients were already in a state of vitamin D insufficiency. 
(Supplementary Table 1, only online)
Most effects of vitamin D are mediated via the vitamin 
D3 receptor (VDR).24 The immune modulator properties of 
vitamin D are ascribed to its effect on T and B lymphocytes, 
all of which harbor VDRs. Vitamin D has been shown to 
inhibit dendritic cell-dependent T-cell activation, and pro-
mote tolerogenic properties that favor the induction of regu-
latory rather than effector T cells.25 In addition, in vitro stud-
ies have shown that activation of CD4 T cells expressing 
VDR by vitamin D promotes a Th2 phenotype (with IL-4 
and IL-5 production) while suppressing Th1 activity (with 
interferon-gamma and IL-2 production).26,27 Through such 
mechanisms, vitamin D is thought to modulate cell-mediat-
ed immune responses and regulate inflammatory T-cell ac-
tivity.28 Low vitamin D may increase the degree of autoim-
munity and subsequently increase the prevalence of AITDs, 
which are the most common autoimmune diseases. Further-
more, the recent surge in prevalence of AITDs may be relat-
trasonography and thyroid function test (Table 3).
DISCUSSION
According to the nationally representative study recently per-
formed in Korea, the mean serum vitamin D level in the Ko-
rean female population was determined to be 18.2 mg/dL, 
and the prevalence of vitamin D insufficiency was 64.5%.15 
This prevalence is remarkably high compared to that of the 
male population. AITDs are the most common endocrine 
disease as well as the most common autoimmune diseases. 
They have been reported to be prevalent in 1-2% of all 
males and 7-9% of all females.17 The fact that both vitamin 
D deficiency and AITDs are predominantly found in wom-
en signifies a certain association between these two condi-
tions. For example, one recent study reported a link between 
vitamin D deficiency and the presence of anti-thyroid anti-
bodies.8 In addition, our study demonstrated a negative as-
sociation between 25(OH)D3 and TPOAb levels, and have 
also shown that the low 25(OH)D3 level is a possible risk 
factor of TPOAb positivity. 
The pathophysiology of AITDs is diverse and includes 
genetic and environmental factors, as well as hormonal in-
fluences.18 The relationship between inflammatory cyto-
kines and AITDs is especially well accepted, and the occur-
rence of AITDs after administration of interferon-alpha has 
been reported and well known.19 Taking into consideration 
the regulatory effect of vitamin D on inflammatory re-
sponses and autoimmunity, such reports support the possi-
ble relationship between AITDs and vitamin D deficien-
cy.20-22 Previous prevalence studies have argued that vitamin 
D deficiency is one of the features of AITDs, especially that 
of Hashimoto’s thyroiditis.23 Our study not only supports 
the existing argument on the association between vitamin D 
and AITDs but also further solidifies the association by re-
vealing that 25(OH)D3 has a statistical correlation with 
TPOAb titer in AITDs patients. 
This study has not shown a difference in vitamin D level 
related to thyroid function or entity of the disease. This sug-
gests that vitamin D deficiency is more closely related to 
anti-thyroid antibody titer rather than thyroid function itself 
in humans, and also agrees with the existing study on pa-
tients with Hashimoto’s thyroiditis.23 We suggest that vita-
min D functions as an immune modulator in autoimmune 
thyroiditis and that the molecular mechanism should be fur-
ther investigated to clarify the causal relationship between 
Table 3. Multiple Logistic Regression Analysis with TPOAb 
(+) as a Dependent Variable
β (95% CI) p value
Age 0.975 (0.945-1.018) 0.256
Gender 0.382 (0.232-1.511) 0.249
BMI 1.100 (0.974-1.321) 0.311
Nodule 1.628 (0.853-1.991) 0.415
DT 0.561 (0.369-1.385) 0.485
fT4 0.811 (0.530-1.024) 0.395
lnTSH 1.000 (0.983-1.092) 0.789
lnVitD 0.917 (0.858-0.953) 0.039
Goiter 1.136 (0.893-1.247) 0.830
TPOAb, anti-thyroid peroxidase antibody; CI, confidence interval; BMI, 
body mass index; DT, diffuse thyroiditis (ultrasonographic findings); fT4, 
free T4; lnTSH, log-transformed thyroid stimulating hormone; lnVitD, log-
transformed 25(OH)D3 level.
Dong Yeob Shin, et al.
Yonsei Med J   http://www.eymj.org   Volume 55   Number 2   March 2014480
5. Huisman AM, White KP, Algra A, Harth M, Vieth R, Jacobs JW, 
et al. Vitamin D levels in women with systemic lupus erythemato-
sus and fibromyalgia. J Rheumatol 2001;28:2535-9.
6. Shapira Y, Agmon-Levin N, Shoenfeld Y. Mycobacterium tuber-
culosis, autoimmunity, and vitamin D. Clin Rev Allergy Immunol 
2010;38:169-77. 
7. Hyppönen E, Läärä E, Reunanen A, Järvelin MR, Virtanen SM. 
Intake of vitamin D and risk of type 1 diabetes: a birth-cohort 
study. Lancet 2001;358:1500-3.
8. Kivity S, Agmon-Levin N, Zisappl M, Shapira Y, Nagy EV, 
Dankó K, et al. Vitamin D and autoimmune thyroid diseases. Cell 
Mol Immunol 2011;8:243-7.
9. Proal AD, Albert PJ, Marshall TG. Dysregulation of the vitamin D 
nuclear receptor may contribute to the higher prevalence of some 
autoimmune diseases in women. Ann N Y Acad Sci 2009;1173: 
252-9.
10. Goswami R, Marwaha RK, Gupta N, Tandon N, Sreenivas V, To-
mar N, et al. Prevalence of vitamin D deficiency and its relation-
ship with thyroid autoimmunity in Asian Indians: a community-
based survey. Br J Nutr 2009;102:382-6. 
11. Lips P, Hosking D, Lippuner K, Norquist JM, Wehren L, Maalouf 
G, et al. The prevalence of vitamin D inadequacy amongst women 
with osteoporosis: an international epidemiological investigation. 
J Intern Med 2006;260:245-54.
12. Holick MF. High prevalence of vitamin D inadequacy and impli-
cations for health. Mayo Clin Proc 2006;81:353-73.
13. Greene-Finestone LS, Berger C, de Groh M, Hanley DA, Hidiro-
glou N, Sarafin K, et al. 25-Hydroxyvitamin D in Canadian adults: 
biological, environmental, and behavioral correlates. Osteoporos 
Int 2011;22:1389-99. 
14. Gordon CM, Feldman HA, Sinclair L, Williams AL, Kleinman 
PK, Perez-Rossello J, et al. Prevalence of vitamin D deficiency 
among healthy infants and toddlers. Arch Pediatr Adolesc Med 
2008;162:505-12. 
15. Choi HS, Oh HJ, Choi H, Choi WH, Kim JG, Kim KM, et al. Vita-
min D insufficiency in Korea--a greater threat to younger genera-
tion: the Korea National Health and Nutrition Examination Survey 
(KNHANES) 2008. J Clin Endocrinol Metab 2011;96:643-51. 
16. McGrogan A, Seaman HE, Wright JW, de Vries CS. The inci-
dence of autoimmune thyroid disease: a systematic review of the 
literature. Clin Endocrinol (Oxf) 2008;69:687-96. 
17. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado 
thyroid disease prevalence study. Arch Intern Med 2000;160:526-
34.
18. Volpe R. The pathophysiology of autoimmune thyroid disease. 
Endocr Regul 1991;25:187-92.
19. Prummel MF, Laurberg P. Interferon-alpha and autoimmune thy-
roid disease. Thyroid 2003;13:547-51.
20. Arnson Y, Amital H, Shoenfeld Y. Vitamin D and autoimmunity: 
new aetiological and therapeutic considerations. Ann Rheum Dis 
2007;66:1137-42.
21. van Etten E, Mathieu C. Immunoregulation by 1,25-dihydroxyvi-
tamin D3: basic concepts. J Steroid Biochem Mol Biol 2005;97: 
93-101.
22. Cantorna MT. Vitamin D and its role in immunology: multiple 
sclerosis, and inflammatory bowel disease. Prog Biophys Mol 
Biol 2006;92:60-4. 
23. Tamer G, Arik S, Tamer I, Coksert D. Relative vitamin D insuffi-
ciency in Hashimoto’s thyroiditis. Thyroid 2011;21:891-6.
24. Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson 
ed to vitamin D deficiency, whose prevalence is also rising.
However, this study does not prove a causal effect of vi-
tamin D insufficiency in the pathogenesis of AITDs. There 
have been no results of interventional study proving the ef-
fect of vitamin D supplements on human subjects with 
AITDs; furthermore, some argue that vitamin D insuffi-
ciency more commonly found in AITDs is the result of the 
pathogenesis of AITDs and its subsequent effect, such as 
VDR dysfunction.9,29 Therefore, further studies on this sub-
ject are required.
The limitations of this study include the retrospective na-
ture of the study and the pool of patients who visited our 
tertiary hospital from which our population was sampled. 
We did not measure anti-thyroglobulin antibody and thyro-
globulin. Hence, we could not investigate the relationship 
between vitamin D and these parameters. Furthermore, clin-
ical parameters associated with thyroid disease, such as cig-
arette smoking, were not available. Thus, we could not in-
vestigate the relationship between smoking and autoimmune 
disease and AITDs. However, such limitations might not 
impact on the relationship between TPOAb and vitamin D 
levels established in this study. 
In conclusion, this study found a clear association be-
tween 25(OH)D3 and TPOAb levels in AITDs, and con-
firmed 25(OH)D3 to be an independent factor related with 
the presence of TPOAb. The causal effects of low vitamin 
D level on thyroid autoimmunity and whether vitamin D 
replacement is helpful to the patients with AITDs required 
future validation.
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